Clinical Scorecard: Height Development and Final Stature in Danish Transgender Youth Undergoing GnRH Analog and Hormonal Therapy
At a Glance
Category
Detail
Condition
Height development in transgender youth undergoing GnRH analog and hormonal therapy
Key Mechanisms
GnRH analog treatment affects height SDS trajectories; estradiol initiation may increase height SDS in some individuals
Target Population
Transgender youth (trans girls and trans boys) in Denmark
Care Setting
Endocrinology and transgender health clinical settings
Key Highlights
Most trans girls had last recorded heights within ±2 SD for cis boys, with some exceeding +2 SD compared to cis girls.
Height SDS declined during GnRHa treatment and increased for some after starting estradiol in trans girls.
Nearly half of trans boys had last recorded heights below −2 SD for cis boys, with stable height SDS trajectories during hormone therapy.
Guideline-Based Recommendations
Diagnosis
Use Danish reference standards for cis boys and cis girls to evaluate height SDS in transgender youth.
Management
Monitor height SDS trajectories during GnRHa and hormonal therapy.
Consider the impact of estradiol initiation on height in trans girls.
Monitoring & Follow-up
Track last recorded height SDS relative to cisgender reference populations throughout treatment.
Risks
Potential for reduced height SDS during GnRHa treatment.
Risk of trans boys achieving height below −2 SD for cis boys.
Patient & Prescribing Data
Danish transgender youth undergoing GnRHa and hormonal therapy
Height SDS trajectories decline during GnRHa treatment; estradiol may increase height SDS in some trans girls; height SDS remains stable in trans boys during hormone therapy.
Clinical Best Practices
Regularly assess height SDS using appropriate cisgender reference standards.
Adjust monitoring protocols to account for changes during GnRHa and estradiol therapy.
Inform patients and families about expected height development patterns during treatment.
